Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288137 | 1.00 | ROCK2 (0.53) | ROCK2ROCK1LMNACNR1MAOA | |
| SCHEMBL3293154 | 0.86 | KDM1A (0.52) | ROCK2ROCK1MAOASMN1; SMN2NPSR1 | |
| SCHEMBL3293152 | 0.86 | KDM1A (0.52) | ROCK2ROCK1MAOASMN1; SMN2NPSR1 | |
| SCHEMBL3290520 | 0.85 | CA1 (0.63) | LMNAKDM1AALDH1A1KCNMA1 | |
| SCHEMBL3290518 | 0.85 | CA1 (0.63) | LMNAKDM1AALDH1A1KCNMA1 | |
| SCHEMBL3288027 | 0.81 | ROCK2 (0.61) | ROCK2ROCK1LMNAMAOASMN1; SMN2 | |
| SCHEMBL12860018 | 0.79 | HTR2C (0.43) | ROCK2ROCK1CNR1MAOAKDM1A | |
| SCHEMBL3287731 | 0.79 | LMNA (0.51) | LMNAALDH1A1KCNMA1 | |
| SCHEMBL3287735 | 0.79 | LMNA (0.51) | LMNAALDH1A1KCNMA1 | |
| SCHEMBL3287740 | 0.79 | LMNA (0.51) | LMNAALDH1A1KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | AR, ADRA2A, ADRA1A | ROCK2 1323/4885ROCK1 1783/4885LMNA 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.